TNDM Advancing Diabetes Technology With Ultra-Rapid Acting Insulin The t:slim X2 insulin pump, equipped with Control-IQ AID technology, is recognized for its ability to improve diabetes management ...

The global rapid acting insulin market was valued at $7,100 million in 2019, and is projected to reach $8,925 million by 2027 at a CAGR of 4.1% from 2020 to 2027. The growth of the global rapid acting ...

In 1985, Novo Nordisk pioneered production of recombinant human insulin in yeast. In 1999, we introduced rapid-acting and, in 2004, long-acting insulin analogues produced by genetic engineering ...

The initial therapeutic focus is diabetes, with three insulin-based products in development. Lead product is an ultra-rapid acting insulin, which the company hopes will outperform market rivals ...

Afrezza is a novel, ultra rapid-acting mealtime insulin therapy being developed for the control of hyperglycemia. The inhaled insulin device proved to be more effective than injected and oral ...

The present patient, who had diabetic nephropathy and retinopathy as secondary complications, was prescribed intensification therapy of subcutaneous injection of insulin (ultra-rapid-acting ...